Drug Approval | March 22, 2023
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans
The objective of launching these products at AAHAR is to create awareness on the consumption of protein based products
Man Industries (India) Limited has received a new export order of approximately Rs. 1,300 crores.
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Proposed combination enhances Pfizer’s position as a leading company in oncology
Kyndryl's multi-cloud management solution leverages AI-based, cloud-hosted models to provide real-time metrics, events, logs, and traces
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Subscribe To Our Newsletter & Stay Updated
